Navigation Links
NIH researchers highlight progress, path forward for developing TB vaccines
Date:3/19/2012

In the past decade, scientists have made significant progress building the critical knowledge and infrastructure needed to identify and develop novel tuberculosis (TB) vaccine candidates and move the most promising ones into human clinical trials. The results of those trials, coupled with advances from other TB studies, have paved the way for the next 10 years of research on TB vaccines, a critical component of TB control efforts, note scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their editorial, co-authored by NIAID Director Anthony S. Fauci, M.D., and Christine Sizemore, Ph.D., appears in the journal Tuberculosis to coincide with the publication of Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade.

The new Blueprint on TB vaccines updates the original one, which was published in 2000 as the result of an NIH-sponsored workshop.

Since that time, TB researchers have assembled a significant pipeline of vaccine candidates and assessed them in clinical trials. However, to transform the field and help make licensure of new vaccines a reality, the editorial co-authors stress, scientists must investigate remaining fundamental questions, including the following:

  • Why does infection with the TB bacterium cause active disease in some people but not others?
  • Why does the current licensed TB vaccine, Bacille Calmette-Gurin, protect children more effectively than adults?
  • What immune responses must effective vaccines elicit to successfully protect against TB?

NIAID, part of the team that helped to develop both iterations of the Blueprint, supports scientists working worldwide to contribute important data to these and other areas of inquiry. The authors also note that along with basic and clinical trial data, recent innovations in systems biology, genomics and bioinformatics, animal modeling, and immunologic and molecular tools will play important roles in developing safe and effective TB vaccines. The authors emphasize that close coordination among biomedical researchers, product developers, funders and TB health care programs worldwide will be essential to eventually develop and deliver new vaccines as part of the global fight against TB.


'/>"/>

Contact: Nalini Padmanabhan
padmanabhannm@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Penn researchers find mentoring provides health benefits for African American veterans with diabetes
2. Mayo Clinic researchers building melanoma vaccine to combat skin cancer
3. Evidence builds that meditation strengthens the brain, UCLA researchers say
4. Wilmot researchers create new way to study liver cancer
5. Researchers develop first theranostic treatment for acute lymphoblastic leukemia (ALL)
6. Researchers find possible genetic keys to surviving epithelial ovarian cancer
7. Researchers discover possible approach to the treatment of aggressive breast cancer
8. Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder
9. Researchers find sarcoma tumor immune response with combination therapy
10. Mayo researchers provide atomic view of a histone chaperone
11. Researchers find potential solution to melanomas resistance to vemurafenib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing and ... compliance with FDA rules. , The FDA has issued two draft guidances that ...
(Date:9/21/2017)... ... September 21, 2017 , ... In addition to sticking with ... more holistic approach and use natural alternatives for all house cleaning products, disinfectants, ... USDA guaranteeing that, the new line of essential oils, are all 100% organic ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, ... Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on Lower East ... pieces, such as Zen Kodo mat. Wanderlust , one of the largest US ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... serving communities in northern Alabama and Georgia, is embarking on an extended charity ... utilizing modern early detection methods. , US Breast Cancer statistics show that ...
(Date:9/20/2017)... ... September 20, 2017 , ... Collins Concrete ... for clients that rely on safety and cleanliness. This unique flooring system uses ... has been used for centuries for its antimicrobial properties. Unlike antibiotics, which kill ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Medicine Technology: